NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Innoviva, Inc. (INVA) Stock Analysis

Innoviva, Inc. (INVA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

INVA

$20.91

−$0.37 (−1.74%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INVA with… →

INVA Key Statistics

As of Oct 21, 2026
Trading
Open
$21.20
Previous Close
$21.28
Day's Range
20.89–21.36
52-Week Range
17.22–25.15
Volume
441.92K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.38
Valuation
Market Cap
$1.51B
P/E Ratio
4.89
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.46
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
3.11
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.43
EPS (ttm)Profit attributable to each share over the last twelve months.
4.28
Financials (FY)
Revenue (FY)
$411.33M+14.67%
Net Income (FY)
$271.17M+1,059.22%
Profit marginThe share of revenue left as profit after all costs and taxes.
81.19%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
72.25M
1-Year Return
+20.17%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
775.84K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, INVA closed at $20.91, +20.17% over 1 year.

Innoviva, Inc. (INVA) has a market capitalization of $1.51B.

In fiscal 2025, INVA reported revenue of $411.33M.

INVA Stock Return by Calendar Year

Innoviva, Inc. (INVA) 10-year return: what $10,000 became

1 year
$10,000 $12,017
+20.17%
5 years
$10,000 $12,734
+27.34%
10 years
$10,000 $20,847
+108.47%

If you had invested $10,000 in Innoviva, Inc. (INVA) 10 years ago, at the close on October 21, 2016, it would have been worth $20,847 at the close on October 21, 2026: +108.47% in total, +7.62% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+4.60%
2025+15.22%
2024+8.17%
2023+21.06%
2022−23.19%
2021+39.23%
2020−12.50%
2019−18.85%
2018+22.97%
2017+32.62%
2016 (partial year)−14.47%

As of October 21, 2026.

INVA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$411.33M$271.17M65.9%
2024$358.71M$23.39M6.5%
2023$310.46M$179.72M57.9%
2022$331.34M$213.92M64.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$411.33M$333.94M$163.75M$271.17M65.9%
2024$358.71M$322.11M$166.87M$23.39M6.5%
2023$310.46M$267.82M$113.89M$179.72M57.9%
2022$331.34M$317.55M$207.00M$213.92M64.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INVA Valuation vs Biotechnology Median

Median of 608 stocks
MetricINVABiotechnology medianvs median
P/E4.8916.600.3x the median
P/S ratio3.4313.300.3x the median
Profit margin81.19%−38.31%119.5 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Innoviva, Inc. (INVA) is capitalised at $1.51B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 159 employees.

The 52-week range on file runs from $17.22 to $25.15. The most recent close on file for INVA is $20.91, dated October 21, 2026. That is −$0.37 (−1.74%) against the previous close. The latest close sits 21.43% above that 52-week low.

Financial Health

In fiscal 2025, Innoviva, Inc. reported revenue of $411.33M. That is +14.67% against the prior fiscal year, when revenue was $358.71M. The same year closed with net income of $271.17M. That is +1,059.22% against the prior fiscal year. Profit margin runs at 81.19%. That is 119.5 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 4.28.

Across the 4 fiscal years on file, revenue moves from $331.34M in 2022 to $411.33M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 4.89 times earnings. That is 0.3 times the Biotechnology median of 16.6. The forward P/E on file is 9.46. The PEG ratio, which sets the P/E against expected earnings growth, reads 3.11. The price-to-sales ratio is 3.43. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.38. Annualized volatility over the trailing 10 years is 33.39%. The trailing one-year total return is +20.17%. Measured over 10 years, that is +7.62% a year compounded.

Growth & Income

No dividend is on file for INVA.

So far in 2026 the total return is +4.60%. The strongest complete calendar year on file is 2021 at +39.23%; the weakest is 2022 at −23.19%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Innoviva, Inc. (INVA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Innoviva, Inc. INVA $1.51B 4.9
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Innoviva, Inc. trades at a P/E of 4.9.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Innoviva, Inc.

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Visit website →